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AbsTrAcT
Recreational diving is increasing in popularity globally, also among European travellers. Since a majority 
of popular diving sites are located in tropical or subtropical destinations commonly characterised by harsh 
climate and poor sanitation, travellers planning to engage in recreational diving are recommended to take 
certain health prevention measures to reduce travel-associated health risks. They need to be aware of the 
fact that diving can threaten their lives or even be fatal; however, if they are well prepared physically and 
mentally and follow all the recommended safety rules while underwater, diving is an unforgettable expe-
rience that cannot be compared to any other sports activity performed on land. Before going on a diving 
trip, it is important to make the necessary arrangements, bearing in mind they should not only concentrate 
on diving-related activities (the marine environment) but also on other aspects, e.g. contact with terrestrial 
flora and fauna. Therefore, the health prevention measures (a pre-travel consultation, vaccinations, antima-
larial chemoprophylaxis, a properly prepared travel health kit and travel insurance) are to keep a traveller 
healthy during the entire travel and not just the moments of going underwater. The most important of the 
pre-travel arrangements include pre-travel medical evaluation, selecting and preparing medications for 
chronic conditions and assembling the first aid kit for personal use. Travellers are recommended to have 
a pre-travel consultation in medical facilities whose personnel have an appropriate level of knowledge and 
expertise on hyperbaric, tropical and travel medicine.  
(Int Marit Health 2017; 68, 4: 215–228)
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VIsIT TO A HEALTH cArE PrOVIDEr
During a pre-travel consultation a doctor will assess the 
health status of a traveller and determine whether he has 
any contraindications to diving. All travellers planning to go 
on a diving trip, especially for the first time, should undergo 
a detailed assessment, including the examination of the 
respiratory, cardiovascular and auditory systems, paranasal 
sinuses and the patient’s mental condition [1]. The past 
medical history of a traveller is also important; particular 
attention should be paid to the following: respiratory system 
illnesses (bronchial asthma), illnesses which can cause loss 
of consciousness (diabetes, epilepsy), mental disorders 
(anxiety), cardiovascular diseases (arterial hypertension, 
coronary heart disease) [2]. Travellers diving regularly should 
undergo such a physical examination periodically. The World 
Recreational Scuba Training Council (www.wrstc.com) has 
introduced the physical examination guidelines for deter-
mining fitness or absolute contraindications to diving. The 
guidelines have been approved by the Divers Alert Network 
(www.diveralertnetwork.org) and the Undersea and Hyper-
baric Medicine Society (www.membership.uhms.org) [3]. 
During the medical evaluation of divers, or candidates 
for divers, their age and sex need to be taken into account. 
Divers > 50 years of age need to be fully aware of their 
limited fitness and abilities as well as contraindications to 
diving associated with the presence of chronic conditions 
or the regular intake of medications. Although there are no 
formal age restrictions, the minimum age for recreational 
diving is 12 years, on condition that the child is physical-
ly and mentally fit for diving (enough physical strength 
to carry scuba equipment, emotional maturity) and has 
no contraindications to diving (e.g. the Eustachian tube 
dysfunction). Apart from pregnancy, there are no specific 
contraindications to diving for women. Women are recom-
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Table 1. Selected medications and their possible adverse effects on divers. Source: [2]
Medications Note
Narcotic/analgesic Narcotic — contraindicated; NSAIDs — no contraindications
Cardiac Some hypotension medications can reduce exercise tolerance
Insulin Blood glucose concentration should be checked before each dive 
Antidepressant Contraindicated
Anticonvulsant Contraindicated
Antimalarial Mefloquine — contraindicated; doxycycline, atovaquone/proguanil — no contraindications
Sympathomimetics Pseudoephedrine can reduce the risk of pressure-related ear injury
Anti-motion sickness Cause sedation, impair the activity of central nervous system 
NSAIDs — non-steroidal anti-inflammatory drugs
mended to avoid diving during menstruation if it triggers 
migraine headaches [1]. 
A large proportion of recreational divers are treated for 
chronic conditions or receive medications (e.g. antimalarial 
chemoprophylaxis) which have no effect on diving. Yet, it 
needs to be remembered that some medications are con-
traindicated for divers (Table 1). Individuals planning to go 
diving who have just started a new drug regimen should 
report any adverse effects that have occurred to their health 
care provider so that the medication can be changed before 
travel [4–6]. 
According to the Divers Alert Network, cardiovascular 
diseases are the second most common cause of fatalities 
among divers [7]. Therefore, special attention needs to be 
given to cardiological patients during the medical assess-
ment of divers or candidates for divers. Mild-to-moderate 
asthma with normal spirometry should not be considered 
an absolute contraindication to diving [8]. According to the 
guidelines for medical assessment of divers, diabetic pa-
tients must receive a fixed-dose insulin therapy for at least 
12 months or oral antidiabetic agents for at least 3 months 
before a dive, the glycated haemoglobin level should be 
≤ 9%, and there should be no episodes of hyperglycaemia 
or hypoglycaemia for 12 months before diving [9]. 
The aim of a pre-travel consultation is to discuss div-
ing-related issues, but in order that a doctor could recom-
mend appropriate prevention measures, a patient must also 
be ready to talk about the following: the itinerary (country, 
part of the world, height above sea level, climate, sanitary 
conditions), the length of stay, departure and return dates, 
the type of accommodation (a hotel, a low-cost hostel), types 
of activities they are going to undertake (a beach holiday, 
scuba diving, mountain climbing, jungle or desert expedi-
tions, cave exploration), vaccinations received (primary, 
complementary or booster doses), the use of antimalarials, 
allergies to food products, cosmetics, medications or egg 
white protein (ingredient of vaccines), chronic or ongoing 
conditions, currently taken medications, carriage of infec-
tious diseases, immunodeficiency, pregnancy [10–12]. 
Diving-related morbidity is not much different from mor-
bidity rates associated with other forms of physical activity. 
The estimated incidence of decompression sickness is 
5–80 cases per 100,000 dives [13]. The risk of death 
among the American and European Divers Alert Network 
is estimated at 1/6,000 dives per year. In comparison, 
the risk of jogging-related death is 1/7,700 joggers per 
year [14]. Officially, drowning is the most common cause 
of death among divers; however, the biggest challenge for 
medical professionals dealing with undersea medicine are 
problems associated with the supply of air/air mixtures, 
a too fast ascent or the presence of conditions which are 
contraindications to diving [7, 14].
MANDATOrY AND rEcOMMENDED  
VAccINATIONs
According to the World Health Organisation (WHO) guide-
lines, international travellers are required to receive vaccina-
tions against two infectious diseases: invasive meningococ-
cal disease and yellow fever. The former is compulsory for 
Muslim pilgrims to Saudi Arabia, while the latter is mandatory 
for travellers to disease endemic countries (30 countries in 
Africa and 13 in Central and South America) (Table 2), as well 
as for short term-travellers to the above-mentioned countries 
(even if it is a 12 h transit) further travelling to one of the 
 90 countries listed by the WHO (interestingly, vaccination is 
not compulsory in Chile and Uruguay — the only South Amer-
ican countries free from the yellow fever transmission, but is 
mandatory for travellers to Albania and Malta, i.e. European 
countries which is free from transmission) [15].
YELLOw fEVEr
Yellow fever is an especially dangerous, infectious 
disease caused by a virus of the Flaviviridae family. The 
infection is transmitted through a  bite from an infected 
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Table 2. Epidemiology of yellow fever 
continents countries 
Africa Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Congo, Chad, Ivory Coast,  
Democratic Republic of Congo, Equatorial Guinea, Ethiopia, Gabon, Gambia, Ghana, Guinea,  
Guinea-Bissau, Kenya, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Somalia, Sudan,  
South Sudan, Togo, Uganda
Central and South America Argentina, Bolivia, Brazil, Ecuador, Guiana, French Guiana, Colombia, Panama, Paraguay, Peru, Suriname, 
Trinidad and Tobago, Venezuela
mosquito of the Aedes, Haemagogus or Sabethes genus. 
The disease is often asymptomatic; however, in severe cas-
es the infection can be fatal. Typical signs and symptoms 
include: fever, headaches, chills, nausea, fatigue, jaundice 
and a red eye. Some patients exhibit severe complications 
including liver or renal failure as well as gastrointestinal 
bleeding (haemorrhagic fever). 
The risk for travellers. The risk of contracting yellow 
fever is 10 times higher in Africa than in South America. 
In western parts of Africa, the disease is most commonly 
transmitted during the late wet season and the early dry 
season (July–October). In South America, the virus is most 
commonly found in Brazil and Peru (the risk of transmission 
is particularly high during the wet season lasting from Jan-
uary until March). The estimated risk of acquiring a severe, 
potentially fatal, form of yellow fever during a 2-week trip to 
endemic areas for an unvaccinated traveller is 1:2,000– 
–1: 10,000 in Africa and 1:20,000 – 1: 100,000 in Central 
and South America [16]. 
Prevention. Vaccination is the best way to prevent yel-
low fever (95% of vaccinated individuals confer immuni-
ty against the yellow fever virus). In many countries the 
vaccination against yellow fever is mandatory and foreign 
visitors are required to present The International Certif-
icate of Vaccination before they can enter the country. 
A  live attenuated vaccine containing 17 DAKAR strain 
of the yellow fever virus is available in Poland (Stamaril). 
According to the resolution WHA67.13 adopted by the 
World Health Assembly on 11th July 2016 booster doses 
against yellow fever are no longer required and a single 
dose of the vaccine is sufficient to confer lifetime immunity 
against the disease. The vaccine should be taken at least 
10 days before travel into endemic areas. The vaccine is 
contraindicated in patients allergic to egg white or other 
vaccine components, children below 6 months, patients 
with congenital, inherited or acquired immunodeficiency 
(e.g. caused by immunosuppressive treatment), patients 
with thymus dysfunction, HIV patients with CD4+ lympho-
cyte count < 200/µL. Special precautions need to be taken 
in children aged 6–8 months, patients > 60 years of age, 
pregnant or breastfeeding women, HIV patients with CD4+ 
lymphocyte count < 200–499/µL [15, 17].
INVAsIVE MENINgOcOccAL DIsEAsE
Invasive meningococcal disease is caused by the Neis-
seria meningitidis bacteria (mainly serogroups A, B and C, 
less commonly Y and W-135). The infection can present as 
the invasive meningococcal disease most commonly man-
ifesting with meningitis or sepsis. The disease is spread by 
droplet transmission, direct or indirect physical contact with 
an infected individual or his secretions. The most common 
clinical signs include sudden paroxysmal fever, headaches, 
neck stiffness, nausea, vomiting, and haemorrhagic rash. 
The disease may have a particularly severe course and lead 
to central nervous system (CNS) damage, multiple organ 
failure, coagulation disorders and eventually death.  
Epidemiology. Neisseria meningitidis is a cosmopolitan 
pathogen. Carriage rates have been estimated to range 
between 5% to 10% worldwide. Outbreaks of the disease 
are primarily reported from areas with large concentrations 
of people (Muslim pilgrimages to Saudi Arabia) and from 
closed environments (military units, prisons, hostels). The 
disease is frequently found in the Sahel, i.e. the countries 
lying between Senegal and Ethiopia, (the so-called ‘men-
ingitis belt’), mostly during the dry season lasting from 
November to June.
Risk for travellers. Travelers to Sub-Saharan Africa, 
to the Sahel region are at the highest risk for developing 
meningococcal infection. The risk increases if a  traveller 
maintains close contact with the local community or stays 
in densely populated areas [17].
Prevention. Vaccination against meningococcal disease 
is recommended for all travellers to endemic areas. The best 
choice for international travellers is a conjugated tetravalent 
meningococcal vaccine against serogroups A,C,Y,W-135. It 
is administered in a single dose (Menveo, Nimenrix); accord-
ing to the manufacturer, booster doses are not required. 
The vaccine ought to be administered at least 2 weeks 
before departure into endemic areas. Vaccination against 
the meningococcal disease is mandatory for all travellers to 
Saudi Arabia going on a pilgrimage to Mecca (travellers are 
required to present a Certificate of Vaccination documenting 
the doses of the tetravalent A, C, W-135, Y vaccine they have 
received). Travelers to Saudi Arabia other than pilgrims are 
not legally required to receive vaccination against meningo-
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coccal disease (unlike the yellow fever vaccine). However, 
the vaccine is strongly recommended and can improve 
health security of travellers to endemic areas. Generally, 
vaccines need to be taken 4–6 weeks before travel so that 
there is enough time to receive all the required doses and 
confer immunity. Yet, even if it is less than 4 weeks before 
departure, travellers are recommended to consult with 
a health care provider in order to obtain the information 
on the possibility of receiving single doses of a vaccine or 
taking an accelerated vaccination course. Travelers who 
received a primary course of vaccinations against infectious 
diseases in the past are recommended to receive boosters 
before departure [17–20]. 
POLIOMYELITIs
Poliomyelitis (the Heine-Medin disease, infantile paraly-
sis) is an acute contagious disease caused by the Poliovirus 
(serotype 1, 2, 3). Currently, only infections with Poliovirus 
type 1 and 2 are being reported (type 3 poliovirus was last 
seen in 2012 in Nigeria). The disease is transmitted through 
a direct physical contact with an infected person or a carrier, 
or contact with their excrement and throat secretions; it can 
be spread by droplet transmission, the faecal-oral route or 
direct contact with objects contaminated with an infected 
person’s faeces or throat secretions. Poliomyelitis can also 
be caused by the use of a live attenuated oral polio vaccine 
(in Poland, OPV was withdrawn from the National Immuni-
zation Schedule in 2016). Between 01.2016 and 09.2017, 
polio cases associated with the circulating vaccine-derived 
Poliovirus (cVDPV) were reported from Syria (40 cases), the 
Democratic Republic of Congo (9), Laos (3), Nigeria (1) and 
Pakistan (1). The majority of polio infections are asymp-
tomatic. In symptomatic cases, the course of the disease 
can be mild to severe. In its most severe form the infection 
causes muscle paralysis which may lead to death. Paralysis 
is observed in 1 per 200 cases; 5–10% of those affected 
by paralysis die, mostly as a result of the respiratory muscle 
paralysis. The disease is most often found in children under 
the age of 5. The virus is excreted with faeces for a period 
of 6 weeks. The virus is most easily transmitted a few days 
before and about 3–4 weeks after the onset of symptoms. 
Humans are the only reservoir of the polio virus [17, 21].
Epidemiology. In 1988, 350,000 poliomyelitis cases 
were reported globally, since then (until August 2017) po-
lio cases have decreased by 99%. Despite this, new polio 
cases are still being observed which is the main reason for 
the delays in global polio eradication program. In its state-
ment of 5 May 2014, the WHO proposed new guidelines on 
polio vaccination, in connection with the risk of importing 
wild Poliovirus (WPV) into polio-free countries. According to 
these guidelines, all residents or long-term travellers (over 
4 weeks) to countries where WPV has been seen, who are 
planning to travel abroad in the next 4 weeks – 12 months, 
should be vaccinated against Poliovirus [15]. Between 2014 
and 2015, 85% of all polio cases were reported from Paki-
stan. In 2016, cases associated with wild polio strains were 
found in Pakistan (20), Afghanistan (13) and Nigeria (4). In 
2017 (until 19 September), WPV poliomyelitis was found 
in Afghanistan (6 cases) and Pakistan (4). This means that 
all residents and long-term travellers staying over 4 weeks 
in polio-affected countries, i.e. Afghanistan, Pakistan and 
Nigeria who are planning to travel abroad should get vacci-
nated against the polio virus. Unless the transmission of the 
wild poliovirus is interrupted in all parts of the world, each 
country previously declared as polio-free is at risk from the 
re-emergence of the polio virus which may potentially lead 
to a new outbreak of the disease [21]. 
Risk for travellers. Vaccination against the Poliovirus is 
recommended for all travellers to or from endemic areas, or 
areas where the virus has re-emerged. Updated information 
on the transmission of wild type Poliovirus can be found on 
the website: www.polioeradication.org, under the tab Data 
and Monitoring [17]. 
Prevention. Poliomyelitis is best prevented by vaccina-
tion against Poliovirus. In Poland immunization against the 
virus is compulsory for all children under 6 years of age (in 
line with the National Immunization Schedule 2017). The 
inactivated poliovirus ()vaccine is administered in 4 doses. 
Adults who were vaccinated against Poliovirus in childhood 
and are travelling to countries where polio cases are being 
reported are recommended a single, inactivated booster 
dose of the vaccine. A number of different vaccines against 
poliovirus are available in Poland, including a monovalent 
vaccine (Imovax Polio), a combination vaccine against poli-
omyelitis, diphtheria, and tetanus (Dultavax) or against poli-
omyelitis, diphtheria, tetanus and pertussis (Boostrix Polio). 
According to the vaccination schedule, patients who have 
been immunised against these diseases should receive 
a single booster dose every 10 years [22]. 
cHOLErA
Cholera is a severe infectious disease of the gastroin-
testinal tract caused by the Vibrio cholerae bacteria. The 
disease is particularly dangerous and if left untreated it 
can lead to death in less than 20 h. The disease is most 
commonly transmitted through the faecal-oral route, i.e. 
consumption of contaminated food or water (most common-
ly fish or seafood), less commonly, through direct physical 
contact with an infected person. The incubation period is 
short and takes from several hours to 5 days. The disease 
usually presents with severe watery diarrhoea. Excessive 
fluid loss and electrolyte imbalance lead to dehydration 
manifesting with dry mucosa, muscle spasms, renal or car-
diac disorders. In severe cases, cholera may lead to a shock 
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and eventually death. According the WHO, approximately 
90% of cholera infections are asymptomatic or mild, espe-
cially among patients living in endemic areas. Therefore, 
in most cases it can be difficult to differentiate between 
cholera and other diarrheal disease if microbiological tests 
are not available. Cholera is highly contagious, and it must 
be remembered that a common source of the infection is 
usually the faeces of an infected person, even if this person 
is asymptomatic [17].  
Epidemiology. The WHO estimates 1.3–4 million new 
cases and 21,000–143,000 deaths from cholera globally 
each year. In its latest full report on cholera prevalence, 
issued in 2015, the WHO reported of 172,000 cases found 
in 42 countries (16 countries in Africa: [Burundi, the Dem-
ocratic Republic of Congo, Ghana, Cameroon, Kenya, Ma-
lawi, Mozambique, Niger, Nigeria, Somalia, South Sudan, 
Tanzania, Togo, Uganda, Ivory Coast, Zimbabwe] — 71,176 
cases; 13 countries in Asia [Afghanistan, Bahrain / import-
ed, Burma, China, India, Iraq, Iran, Japan / imported, Kuwait 
/ imported, Malaysia, Nepal, Oman / imported, Thailand] 
— 64,590 cases; 6 countries in Europe [imported cases in 
France, Spain, Norway, Switzerland, Sweden, United King-
dom] — 22 cases; 6 countries in North and South America 
[the Dominican Republic, Haiti, Canada / imported, Cuba, 
Mexico, the United States of America] — 36,664 cases; 
2 imported cases in Australia), including 1,304 deaths 
(in 23 countries). In 2015, 80% of all cholera cases were 
reported from Afghanistan (58,064 cases), Haiti (36,045), 
the Democratic Republic of Congo (19,182), Kenya (13,291) 
and Tanzania (11,563) [23]. A large cholera outbreak was 
reported from Yemen in April 2017; until 21 September, or 
within 5 months only, over 704,000 cases were diagnosed, 
including 2,103 deaths [24]. Over the last decade, a majority 
of cholera cases were seen in Haiti; 813,000 cases and 
9,676 deaths of cholera were reported there from October 
2010 until mid-August 2017 [25]. 
Risk for travellers. Travellers to cholera endemic areas 
in Africa, Asia and the Caribbean are most at risk of devel-
oping cholera, especially if they tend to ignore the rules 
regarding food and feeding hygiene. 
Prevention. Prevention is primarily concentrated on the 
introduction of effective sanitation and water treatment 
practices. A  traveller to a developing country should pay 
particular attention to proper hygiene practices, especially 
washing hands each time after using the toilet. Also, they 
should always follow the rule: ‘boil it, cook it, peel it or 
forget it’. The disease may be effectively prevented with 
an oral inactivated vaccine. Currently, there are three vac-
cines against cholera recommended by the WHO. These 
are: Dukoral (Valneva, Sweden), Shanchol (manufactured 
in India) and Euvichol (manufactured in South Korea). All 
the vaccines require 2 doses for full protection. Cholera 
vaccines are orally administered, which means patients 
need to abstain from eating and drinking at least 1 h be-
fore and 1 h after receiving the vaccine. Dukoral is the only 
cholera vaccine registered and available in Poland. It is an 
oral vaccine consisting of killed whole-cell V. cholerae O1 
of several strains (Inaba and Ogawa serotypes, classical 
and El Tor biotypes) and purified recombinant cholera B 
subunit (rCTB). The vaccine also provides protection against 
enterotoxic ETEC due to the structural and immunological 
similarities between the LT-ETEC and rCTB (cross protec-
tion). The primary course consists of 2 doses given at an 
interval of 1–6 weeks for children over 6 years and adults 
(in children aged 2–6 years the vaccine is administered in 
3 doses at the intervals of 1–6 weeks). The vaccine confers 
immunity against cholera for the next 2 years in children 
over 6 years of age and in adults (in children aged 2–6 
years the immunity persists for 6 months). After this period, 
a booster dose needs to be administered. All doses of the 
vaccine should be taken at least 1 week before the planned 
departure into endemic areas [15, 17].
TYPHOID fEVEr
Typhoid fever is an acute contagious disease caused 
by Salmonella typhi. The disease is generally transmitted 
through the faecal-oral route, i.e. consumption of contam-
inated water or food. Less frequently, the disease may be 
transmitted through direct physical contact with an infected 
individual or an asymptomatic carrier. The common signs 
and symptoms include: a gradually progressing fever, head-
aches, fatigue, loss of appetite, abdominal pain, diarrhoea 
or constipation, skin rash. A patient may develop severe 
complications including intestinal perforation, peritonitis, 
sepsis, encephalitis or neuropsychiatric disorders [17].  
Epidemiology. Typhoid fever is a cosmopolitan disease. 
The risk of developing an infection is higher in areas lacking 
adequate food and feeding hygiene. Contaminated water 
supply reservoirs may also become the source of infection. 
Globally, an estimated 21 million new cases are reported each 
year; 200,000 of the cases are fatal (data from 2014) [15].   
Risk for travellers. The highest risk for typhoid fever is 
reported in developing countries in Asia, Africa, Central and 
South America. 80% of all typhoid cases are found in South 
Asia (Bangladesh, India, Pakistan, Nepal), South-East Asia 
(Vietnam, Laos) and in China.
Prevention. The most effective method of preventing 
the disease is by vaccination and proper food and feeding 
hygiene, especially for travellers to South and South-East 
Asia planning to use local dining facilities. Currently, there 
are two types of vaccine against typhoid available in Poland: 
a vaccine containing inactivated, heat and formalin-killed 
Salmonella typhi bacteria, and a  vaccine containing the 
purified Vi capsular polysaccharide Vi Salmonella typhi. The 
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vaccines are used to provide protection against typhoid, they 
do not, however, protect against other paratyphoid fevers. 
The inactivated vaccine is administered in 3 doses (month 
0, 1, 6–12); a booster is given every 3–5 years following 
the primary course. The Vi capsular polysaccharide vaccine 
is administered in 1 dose and the efficacy of the vaccine 
lasts for 3 years (following this period a booster dose is 
recommended). The vaccine needs to be taken at least 
1 week before the planned departure [26, 27].   
HEPATITIs A
Hepatitis A  is a disease of the digestive tract caused 
by the hepatitis A virus (HAV). The disease may be asymp-
tomatic, or may present with moderate to severe signs and 
symptoms. The disease can be transmitted through direct 
physical contact with an infected person but also through 
the faecal-oral route, i.e. drinking contaminated water or 
beverages (also contaminated ice cubes), eating shellfish 
caught from contaminated waters, consumption of raw fruit 
and vegetables. HAV is resistant to freezing; frozen foods 
can be the source of infection as well. The incubation period 
of hepatitis A is typically 2 to 6 weeks, the most common 
signs and symptoms include fever, loss of appetite, nausea, 
vomiting and jaundice. The virus is excreted with faeces for 
a period of 6 weeks but is easily transmitted 2–-3 weeks 
before symptoms appear. 
Epidemiology. Viral hepatitis A  is a cosmopolitan dis-
ease, i.e. it is found worldwide. The endemicity level much 
depends on the geographical region and the level of hygiene 
and standards of sanitation in a given area.  
Risk for travellers. The risk of infection with viral hepatitis 
A increases in areas with poor standards of hygiene and sanita-
tion, especially if foreign visitors use local dining facilities [17]. 
Prevention. To prevent hepatitis A, travellers need to 
maintain good food and feeding hygiene, but the best way 
to avoid infection is to get vaccinated. The monovalent inac-
tivated HAV vaccines available in Poland are administered 
in 2 doses at the interval of 6–12 months (according to 
the manufacturers, the second dose of Avaxim should be 
taken no later than 36 months after the initial dose, while 
the second dose of Havrix Adult needs to be received no 
later than 5 years after the primary course). The first dose 
of the vaccine should be taken at least 2–4 weeks before 
travel. The WHO does not recommend the administration 
of a  booster dose (the level of antibodies produced af-
ter the primary course of vaccination persists for at least 
25 years). A combined vaccine against hepatitis A and B is 
also used in Poland; it is administered in 3 doses at months 
0, 1, 6. Also, an accelerated combined vaccination course 
is available: the vaccine is taken on days 0, 7, 21, and 
patients receive a single booster dose 12 months after the 
primary course [28, 29].  
HEPATITIs b
Hepatitis B is a contagious disease caused by the lym-
photropic and hepatotropic hepatitis B virus (HBV). HBsAg, 
the surface antigen of the hepatitis B virus, is responsible 
for its strong immunogenicity. HBV strains have been clas-
sified into four groups (ayw, adw, ayr, adr); all of the strains 
have the same clinical presentation. The common modes of 
transmission include: blood transfusion or blood products 
transfusion, direct contact with infected bodily fluids (saliva, 
mucus, sperm), sexual contacts, vertical transmission, i.e. 
from a mother to her baby, accidental or deliberate punc-
tures with contaminated needles (e.g., accidental needle-
stick injuries, re-use of contaminated needles and syringes, 
piercing, tattooing, acupuncture). Hepatitis B infection may 
be asymptomatic or it may present with moderate to se-
vere signs and symptoms. In some cases it may develop 
into a chronic form and eventually lead to cirrhosis or liver 
cancer. HBV infected individuals are the major source of 
transmission. HBV is much more infectious than HIV and 
it is more resistant to environmental factors and chemical 
agents. The most common symptoms of HBV infection in-
clude fatigue, loss of appetite, nausea, abdominal pain and 
jaundice. The incubation period is normally 3–4 months but 
it can range between 6 weeks and 6 months [17]. 
Epidemiology. Hepatitis B is a cosmopolitan disease. 
According to WHO, an estimated 257 million people world-
wide are infected with the hepatitis B virus. In 2015, hep-
atitis B was the cause of 887,000 deaths, mostly from 
complications such as liver cancer or cirrhosis. The highest 
prevalence rates of HBV infections are reported from Africa 
and Oceania (over 6% of the adult population), in the Middle 
East, Central Asia and North-East Africa (3.3% of the gen-
eral population) and South-East Asia (2.0% of the general 
population) [15]. 
Risk for travellers. The main factors determining the 
risk of infection with HBV while traveling overseas are: 
high incidence of the disease in a  given population and 
exposure to infectious blood or other bodily fluids. The risk 
of becoming infected with hepatitis B increases if travellers 
engage in casual sex or receive injections (medications, 
intravenous drugs).
Prevention. While travelling to endemic countries, trav-
ellers should avoid casual sexual contacts and exposure 
to contaminated needles (piercing, tattoos). Yet, the most 
effective form of prevention against hepatitis B is vaccina-
tion. There are several monovalent hepatitis B vaccines 
available in Poland. Each contains a different dose of HBsAg, 
depending on the manufacturer (Engerix B, Euvax, HBVAX 
PRO). The vaccines are administered in 3 doses (months 
0, 1, 6). No less than 2 doses of the vaccine should be 
administered at least 2 weeks before travel. A combined 
vaccine against hepatitis A and B (a single injection) is also 
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used in Poland; it is administered in 3 doses at months 
0, 1, 6. An accelerated combined vaccination course is 
given on days 0, 7, 21; patients receive a single booster dose 
12 months after the primary course. According to the WHO 
recommendations it is not necessary to receive a booster 
dose of a HBV vaccine since the level of antibodies produced 
after the primary course of vaccination persists for many 
years after. To assess the response to HBV vaccine, the 
anti-HBs antibodies test is performed (in non-vaccinated 
patients, the presence of anti-HBs antibodies indicates 
a HBV infection in the past). The test is performed no earlier 
than 4 weeks after the administration of the last dose of the 
primary immunisation course (best between week 4 and 6). 
The concentration of the anti-HBs antibodies should be 
higher than 10 IU/L (however, according to the National 
Immunisation Programme, even if the concentration of the 
anti-HBs antibodies is lower than 10 IU/L booster doses are 
not required for previously vaccinated healthy individuals). 
A  booster dose or a  regular anti-HBs test (every 6–12 
months) is only recommended for patients with renal dis-
eases and the glomerular filtration rate less than 30 mL/min 
and for dialysis patients [30–32]. 
DIPHTHErIA
Diphtheria is an acute bacterial disease caused by tox-
ic strains of Corynebacterium diphtheriae. It is spread by 
droplet contact or direct physical contact with an infected 
individual. Diphtheria affects the mucous membrane of 
the respiratory tract (upper respiratory tract diphtheria), 
skin, or less commonly, other parts of the body (eyes, nose, 
sex organs). The incubation period is 2–5 days. Diphtheric 
lesions, usually affecting the upper respiratory tract mu-
cosa (throat, tonsils, larynx), are often covered by necrotic 
pseudomembrane. The bacteria produce a toxin which can 
spread through the body and cause serious complications, 
e.g. myocarditis [17].   
Epidemiology. Diphtheria is a  cosmopolitan disease. 
Currently, WHO is promoting and conducting mass DTP3 
(diphtheria, tetanus, pertussis) immunisation campaigns 
targeting children worldwide (an estimated global vaccina-
tion coverage is 86%; the lowest, less than 50% is reported 
from Somalia, South Sudan, Central African Republic, Syria 
and Ukraine). Despite these efforts, diphtheria infections are 
still being reported from South Asia (India), South-East Asia 
(Indonesia, Laos, Burma) and East Africa (Madagascar). In 
2015, a total of 4,530 cases of diphtheria (including 2,365 
in India and 1,627 in Madagascar) were reported globally. 
In 2016, diphtheria prevalence increased in India (3,380) 
and in Madagascar (2,865). 
Risk for travellers. The disease is potentially life-threat-
ening. Severe complications may occur in individuals who 
have not been immunised. The disease is far more common 
in areas where vaccination rates are low among the local 
population [15].
Prevention. In Poland, vaccination against diphtheria 
is a part of the National Immunisation Programme and is 
administered to all children under 19. Patients who have 
been vaccinated in childhood are recommended a single, 
booster dose every 10 years; for patients who have not 
been immunized a  primary course of the vaccination is 
recommended. There are two combination vaccines against 
diphtheria available in Poland; the first one provides pro-
tection against diphtheria, tetanus, poliomyelitis (Dultavax) 
and the other one against diphtheria, tetanus, pertussis 
and poliomyelitis (Boostrix Polio). Adults who have been 
immunized in the past need to receive a booster dose every 
10 years [17, 33]. 
TETANus
Tetanus is an acute infectious disease caused by a neu-
rotoxin produced by anaerobic bacillus Clostridium tetani. 
Infection typically occurs through contamination of a wound 
with soil, animal manure fertilizer, dust or other foreign 
body infected with tetanus spores. The incubation period is 
from 3 days to 3 weeks (usually 8 days). Symptoms of the 
disease include muscle stiffness and painful spasms which 
first develop in the jaw and neck muscles. Severe tetanus 
may lead to respiratory failure and eventually death [17].   
Epidemiology. Contamination of a wound with tetanus 
spores (Clostridium tetani) may occur in any part of the 
world, especially in the developing countries in Africa and 
Asia. Currently, the WHO is promoting mass DTP3 (diphthe-
ria, tetanus, pertussis) immunisation campaigns targeting 
children worldwide (an estimated global vaccination cov-
erage is 86%; the lowest, less than 50% is reported from 
Somalia, South Sudan, Central African Republic, Syria and 
Ukraine). Tetanus prevalence is high in South Asia (India, 
Nepal, Bangladesh, Pakistan), South East Asia (Philippines, 
Vietnam) and East Africa (Kenya, Uganda). In 2015, a total 
of 10,337 tetanus cases were reported globally (including 
2,268 in India and 1,804 in Uganda). In 2016, there was 
an increase in tetanus prevalence in India (3,781), Kenya 
(2,776) and the Philippines (1,082) [15].
Risk for travellers. Basically each type of a puncture 
wound, no matter if it is merely a skin cut or a severe mul-
tiorgan injury, may result in a tetanus infection especially 
in non-vaccinated individuals.  
Prevention. In Poland vaccination against tetanus is 
a part of the National Immunisation Programme and is ad-
ministered to all children under 19. Adult patients who have 
been vaccinated in childhood are recommended a single, 
booster dose to be taken every 10 years; for patients who 
have not been immunised a primary course of the vaccina-
tion is recommended. The vaccine is also recommended for 
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employees whose work responsibilities involve contact with 
soil, workers employed at the disposal of solid and liquid 
waste, and those responsible for the maintenance of devices 
used for that purpose, as well as travellers to tetanus en-
demic countries. There are two combination vaccines against 
tetanus available in Poland; the first one provides protection 
against diphtheria, tetanus, poliomyelitis (Dultavax) and the 
other one against diphtheria, tetanus, pertussis and poliomy-
elitis (Boostrix Polio). Adults who have been immunized in the 
past need to receive a booster dose every 10 years [17, 33]. 
rAbIEs
Rabies is a fatal infectious disease caused by the neu-
rotropic Lyssavirus virus of the Rhabdoviridae family. The 
disease is nearly always transmitted through a bite from an 
infected animal or exposure of damaged skin or mucosa 
to contaminated saliva. The incubation period is on aver-
age 20–29 days, but it may be as long as several months 
(the incubation period is shorter if the bitten site is highly 
innervated). The first signs manifest at the earliest after 
10 days from the virus transmission. In humans, the signs 
and symptoms of rabies include paraesthesia at the site 
of the bite, anxiety, sweating, increased salivation and 
enlarged pupils. An infected person may also experience 
painful muscle spasms while swallowing, breathing difficulty 
and seizures. Death usually occurs in less than a week after 
the onset of initial symptoms [17].  
Epidemiology. Rabies is a cosmopolitan disease. The 
WHO regularly updates the list of countries reporting new 
cases of rabies infections. Currently, the list includes 
90 countries from Asia, Africa, Central and South America. 
There are an estimated 55,000 deaths from rabies world-
wide each year. The infection is most frequently transmitted 
by a bite from infected dogs (95% of human rabies), less 
often from cats, bats, wild predators. A majority of cases 
are reported from India (approx. 20,000 cases annual-
ly), but also from countries in South and South-East Asia 
(Afghanistan, Pakistan, Bangladesh, Nepal, Burma, Cambo-
dia) and Africa (the Democratic Republic of Congo, Burkina 
Faso, Niger, Nigeria, Ethiopia, Somalia, Kenya, Tanzania, 
Mozambique).
Risk for travellers. The highest risk of rabies trans-
mission is from stray dogs. Children under the age of 15 
are at the greatest risk of transmission (40% of all cases) 
because they are smaller than adults and may be bitten 
more severely, also, they are keen to play with animals, and 
if they have been bitten they often fail to inform anyone of 
the fact). Cave explorers need to keep in mind that rabies 
can also be transmitted by bats [17].  
Prevention. Travellers to rabies endemic countries, es-
pecially in Asia and Africa, are recommended pre-exposure 
vaccination. If they are bitten by a potentially infected ani-
mal, they must receive post-exposure vaccination as well. 
They should avoid contact with stray animals, mainly cats 
and dogs, but also with wild undomesticated animals. They 
should never approach, touch or stroke any animals, even 
if they are domesticated and behave in a friendly manner. 
Pre-exposure vaccination against rabies is administered in 
3 doses for both children and adults. The vaccine is given on 
days: 0, 7, 28 (according to the WHO recommendations on 
days: 0, 7, 21 or 28). A complementary dose is administered 
a year after the primary course. In order to increase the vac-
cine efficacy, a booster dose is recommended to be taken 
every 5 years. All three doses of the primary immunization 
course should be taken at least 3 weeks before travel to 
endemic areas. An inactivated rabies vaccine, containing 
a killed virus which is grown in a VERO cell line (Verorab), 
is available and used in Poland [17].    
Post-exposure vaccinations. Patients who have received 
pre-exposure vaccination (in the last 5 years) are given 
2 doses of the vaccine: the first dose on the day of being 
bitten and the second dose 3 days later. Individuals who 
have not been immunised (they received pre-exposure 
vaccination more than 5 years before being bitten, they 
have not received all doses of the vaccine or have never 
taken pre-exposure vaccination) receive 5 doses of the 
post-exposure vaccine on days: 0 (the day of being bitten), 
3, 7, 14 and 28. Before administering the first dose of the 
vaccine, a non-immunized individual should also receive 
immunoglobulin RIG (HRIG: 20 IU/kg body mass or ERIG: 
40 IU/kg body mass) [34].  
JAPANEsE ENcEPHALITIs
Japanese encephalitis is a viral disease affecting the 
CNS caused by the viruses of the Flaviviridae family. The 
disease is transmitted through a bite from an infected mos-
quito. The natural hosts of the Japanese encephalitis virus 
are wading birds that inhabit wetland areas as well as pigs 
bred in rural areas. The majority of cases are asymptom-
atic or present with mild flu-like symptoms including fever, 
headaches and gastrointestinal disorders. A vast majority 
of cases presenting with clinical symptoms is found in chil-
dren under 10 years of age, and 75% of all infections are 
diagnosed in children under 15 years of age. Approximately 
1% of the infected individuals develop disorders of the CNS 
(encephalitis, disorders of consciousness, paresis) with 
mortality rate reaching 30% of those affected [17]. 
Epidemiology. The transmission of Japanese encepha-
litis virus has been reported from 22 countries in Asia and 
from Australia and Oceania (Yorke peninsula, Queensland, 
Papua New Guinea). The WHO estimates nearly 68,000 
clinical cases globally each year, including 10,000–20,000 
deaths. Since most patients with Japanese encephalitis are 
asymptomatic, the reported cases constitute only a small 
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part of the actual number of cases. In 2016, a total of 5,399 
new cases of Japanese encephalitis were reported from 
17 countries. The highest prevalence was reported from 
India (1,627), Bangladesh (1,294), China (1,130), Burma 
(393), Vietnam (357) and the Philippines (312) [15].
Risk for travellers. The risk of contracting Japanese 
encephalitis increases in rural areas or wetland areas — 
a natural habitat for mosquitoes, i.e. vectors of the infection.
Prevention. Because there is no specific causative treat-
ment for Japanese encephalitis, prevention against vectors 
(mosquitoes) of the infection is crucial. To minimise the 
risk of infection travellers are recommended to use insect 
repellents, wear long-sleeved shirts or tops and long trousers 
and avoid staying outdoors after dark, especially in areas 
close to standing water. An inactivated vaccine, containing 
killed Japanese encephalitis virus grown in a VERO cell line 
(Ixiaro), is available and used in Poland. In adults, the vac-
cine is administered in 3 doses: the first dose on day 0, the 
second dose on day 7 or 28, the third — a complementary 
dose is administered 12–24 months after the primary one. 
There are no data available regarding the need to administer 
a booster dose in adult patients. Children over 3 years of 
age receive the vaccination in 2 doses: on day 0 and 28. 
Both doses of the vaccine should be taken at least 7 days 
before travel to endemic areas [35, 36]. 
Vaccinations recommended for travellers to popular 
diving sites are summarised in Table 3.
MALArIA cHEMOPrOPHYLAXIs
Malaria is a protozoan disease caused by five species of 
the Plasmodium genus: P. falciparum, P. vivax, P. malariae, 
P. ovale and P. knowlesi. It is transmitted to humans through 
a  bite from an infected female Anopheles mosquito (by 
injecting invasive Plasmodium forms into the bloodstream 
of a human host), through blood transfusion, or vertically, 
from an infected mother to her child. Plasmodium parasites 
invade the human liver and the red blood cells. The disease 
vectors in malaria-endemic areas are found at the altitude 
of up to 2000–2200 m above the sea level (with the excep-
tion of certain malaria-prone areas in Afghanistan, Bolivia, 
Ethiopia, Eritrea, Kenya and Pakistan where cases of the 
disease are observed at the altitudes of 2200–2500 m 
above the sea level). An estimated 3 billion people in 
95 countries live in malaria-endemic areas. According to 
the estimates from the WHO there were 214 million new 
cases of malaria in 2015 (88% in Africa, 80% in 17 countries 
and as much as 40% in 3 countries only: the Democratic 
Republic of Congo, Nigeria and India. In the same year the 
WHO reported of 438,000 deaths from malaria (90% in 
Africa, 70% in children under the age of 5, 80% cases in 
14 countries, and 47% in 6 countries: Nigeria, the Demo-
cratic Republic of Congo, Tanzania, Uganda, Mozambique 
and Ivory Coast). Plasmodium falciparum and P. vivax are 
the most common etiological factors of malaria global-
ly (80–95% cases). In highly developed countries (North 
America, Western Europe) there are approximately 10,000 
imported malaria cases, mainly from Sub-Saharan Africa 
and South-East Asia. Sporadically, there are reports of the 
so-called ‘airport malaria’, i.e. cases of malaria occurring in 
and near international airports or sea ports and caused by 
infected mosquitoes transported by a ship or aircraft from 
malaria-endemic areas [17]. In Europe, domestic cases 
of malaria were reported from Greece in 2013 and then 
again in 2016 (in total, 12 districts were affected, including 
Thessaloniki and the Peloponnese) [37]. In Poland, 20 to 
30 cases of malaria are diagnosed yearly; all of which are 
imported cases. After an incubation period lasting from 
9 to 40 days depending on the species of Plasmodium, clin-
ical symptoms appear in three typical stages: a cold stage 
accompanied with shivers and chills, a  hot stage during 
which the body temperature reaches 40oC with symptoms 
including dry skin and mucosa, consciousness disturbances, 
abdominal pain due to splenomegaly, and finally a sweating 
stage with a sudden drop in body temperature and massive 
sweating. In Plasmodium vivax and P. ovale infections, fever 
paroxysms occur periodically every 48 h (tertian fever), in 
P. malariae infection — every 72 h (quartan fever). Fever 
paroxysms in P. falciparum malaria are irregular and ele-
vated body temperature of varying degree can persist all 
throughout the duration of the symptomatic disease. Fever 
paroxysms in malaria may be accompanied by headaches, 
muscle pain, nausea, vomiting, diarrhoea, hepatomega-
ly and splenomegaly. Fever paroxysms gradually become 
less severe and if there are no complications, symptoms 
normally disappear within several weeks. P. falciparum 
malaria is the most severe form of malaria and may cause 
serious complications. The mortality rate of P. falciparum 
malaria reaches 15–20%. The life-threatening complica-
tions of severe malaria include: coma, focal CNS damage, 
acute respiratory failure, severe anaemia, thrombocytopenic 
haemorrhagic diathesis and/or disseminated intravascular 
coagulation, acute renal failure. 
The principal preventive measures against malaria include:
 — the use of appropriate malaria drug regimens: atova-
quone/proguanil, doxycycline, mefloquine or chloro-
quine;
 — the use of mosquito nets, insect repellents (containing 
30–50% DEET — N,N-diethyl-meta-toluamide or 20% 
picaridin e.g. Moskito Guard), wearing proper clothing 
(long-sleeved shirts or tops, long trousers);
 — staying indoors after dark (when mosquitoes are the most ac-
tive) especially in areas close to standing water (ponds, lakes);
 — staying in air-conditioned accommodation with insect 
screens on all windows and ventilation grills.
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Philippines X X X X X X X
Indonesia X X X X X X X
Malaysia X X X X X X X
Thailand X X X X X X X
Indian Ocean
Andaman Islands (India) X X X
Maldives X X X
Mauritius X X X
Seychelles X X X
Pacific Ocean
Fiji X X X
Palau X X X
Central America and the Caribbean
Belize X X X X
Cayman Islands X X X
Costa Rica X X X X
Mexico X X X X X X
Red Sea








Tunisia X X X
The Centres for Disease Control and Prevention as well 
as the WHO recommend that travellers to malaria endemic 
areas should use one of the following drug regimens:
 — atovaquone/proguanil — the drug has the fewest side 
effects of all the recommended antimalarials (rarely: 
gastrointestinal disorders, allergic rash, headaches);
 — doxycycline — the drug has a large number of side effects 
and can cause nausea, vomiting, oral or vaginal yeast 
infections, hepatotoxicity, hypersensitivity to sunlight, 
photodermatoses;
 — mefloquine — possible side effects include neuropsychi-
atric disorders, thus the medication is contraindicated 
for some professionals, e.g. aircraft crews;
 — chloroquine — the emergence of chloroquine-resistant 
plasmodium has had a significant impact on the appli-
cation of chloroquine to treat malaria; currently the drug 
www.intmarhealth.pl 225
Krzysztof Korzeniewski Jarosław Krzyżak, Travel medicine for divers
Table 4. Drugs used for antimalarial chemoprophylaxis. Source: [17]




11–20 kg bw: 62.5 mg/25 mg
(paediatric tablet)
21–30 kg bw: 2 paediatric tablets
31–40 kg bw: 3 paediatric tablets
> 40 kg bw: 250 mg/100 mg  
(adult tablet) 1 × 1 tablet
1 day before travel,  
every day during travel,  
7 days after travel
Concurrent intake of metoclopramide 
or tetracycline results in a lower  
plasma concentration of the drug 
very rare gastrointestinal,  
dermatological adverse events
doxycycline 1× day
adults: 1 tablet 100 mg 
1 day before travel,  
every day during travel,  
28 days after travel
Gastrointestinal, dermatological,  
gynaecological adverse events
mefloquine 1 × week
adults: 1 tablet 250 mg
1 week before travel,  
1 × week during travel,  
4 weeks after travel
Concurrent intake of ampicillin, tetra-
cyclines or metoclopramide results in 
a higher plasma concentration of the 
drug neuropsychiatric adverse events
chloroquine 1 × week  
adults: 300 mg (2 tablets 150 mg)
1 week before travel,  
1 × week during travel,  
4 weeks after travel
Contraindicated in epilepsy and  
psoriasis
is only to be used in certain regions of the world (Central 
America, North Africa, some Middle East countries) [17] 
(Tables 4, 5).
sTAND-bY EMErgENcY TrEATMENT (sbET)
In case of a fever of unknown origin occurring in tourists 
travelling to malaria-endemic regions where diagnostic tests 
which might confirm or rule out malaria are unavailable, the 
WHO recommends the self-use of a  stand-by emergency 
treatment. SBET is also advised to contract workers offered 
short-term overseas employment in malaria-endemic re-
gions. Coartem (artemether 20 mg/lumefantrine 120 mg) 
is now the most widely used emergency medication for the 
treatment of malaria. The drug is to be taken in 6 doses 
over 3 consecutive days: 0, 8, 24, 36, 48, 60 (hours) — body 
weight: 5–14 kg: 1 tablet (20 mg/120 mg)/ a single dose; 
15–24 kg bw: 2 tablets (40 mg/240 mg)/a single dose; 
25–34 kg bw: 3 tablets (60 mg/360 mg)/a single dose; 
over 34 kg bw: 4 tablets (80 mg/480 mg)/a single dose. 
SBET is also advised to contract workers offered short-term 
overseas employment (lasting from several days to several 
months) in malaria-endemic regions, if the risk of possible 
side effects associated with standard chemoprophylaxis 
is higher than the risk of malaria transmission. In Switzer-
land and Great Britain arthemeter/lumefantrine has been 
registered for stand-by emergency treatment of malaria in 
travellers [17].
TrAVEL HEALTH KIT
Preparing and packing a travel health kit is as import-
ant as receiving all preventive vaccinations and taking 
antimalarial chemoprophylaxis and/or preparing standby 
emergency treatment of malaria (SBET). Before travelling 
abroad make sure you pack all the necessary medications, 
dressing materials and documents e.g. The International 
Certificate of Vaccination, a health insurance card, a copy 
of your passport and passport photographs which may be 
necessary to obtain entry visas. These include: 
 — prescription medicines for chronic diseases, contraceptive 
medications and antimalarials for the whole period of travel 
(these should be kept in the hand luggage in the original 
packaging in case of a thorough inspection by border guards);
 — when travelling by plane you should keep in mind cer-
tain security requirements on the transport of liquids 
(drugs in the form of suspensions, syrups or cosmetics). 
Liquid containers larger than 100 mL must be placed in 
checked baggage, containers smaller than 100 mL — 
may be carried in the hand luggage, but must be stored 
in a sealed transparent plastic bag;
 — antimalarial medication;
 — insect repellent;
 — antidiarrheal medication;
 — medications for the respiratory tract infections;
 — medications for the urinary tract infections;
 — analgesic, antipyretic;
 — antihistamine;
 — adrenaline prefilled syringe for individuals allergic to 
hymenoptera venom;
 — motion sickness medication;
 — anti-inflammatory/antimicrobial/antifungal ointments 
and creams;
 — after-bite anti-itch gel;
 — skin disinfectants;
 — ear and eye drops;
 — dressing materials (gauze, bandage), scissors, tweezers, 
gloves;
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Table 5. Recommended antimalarial chemoprophylaxis in countries popular among divers. Source: [37]







Rural areas below 600 m above sea level except for 22 provinces: Aklan, 
Albay, Benguet, Biliran, Bohol, Camiguin, Capiz, Catanduanes, Cavite, 
Cebu, Guimaras, Iloilo, Northern Leyte, Southern Leyte, Marinduque, Mas-
bate, Easter Samar, Northern Samar, Western Samar, Siquijor, Sorsogon, 
Surigao Del Norte. No risk of malaria transmission in the country’s capital, 
Manila or in urban areas.
Confirmed atovaquone/proguanil,  
doxycycline or mefloquine
Indonesia Eastern parts of the country (provinces: Maluku, Maluku Utara, Nusa  
Tenggara Timur, Papua and Papua Barat), including the city of Labuan 
Bajo and the Komodo Islands (Nusa Tenggara); rural areas: Kalimantan 
(Borneo), Nusa Tenggara Barat (including the island of Lombok), Sulawesi, 
Sumatra. Low risk of transmission in rural areas in Java (including Ujung 
Kulong, Sukalumi and Pangandaran). No risk of transmission in Jakarta, 
Ubud and in seaside resorts in Bali, Java, Gili Islands and Thousand  
Islands (Pulau Seribu)
Confirmed atovaquone/proguanil,  
doxycycline or mefloquine
Malaysia Rural areas, especially forests in Borneo (Sabah and Sarawak provinces)  
and the peninsula. No risk of transmission In large cities and at the seasi-
de (Kuala Lumpur, Georgetown, Penang State including Penang Island)
Confirmed atovaquone/proguanil,  
doxycycline or mefloquine
Thailand Provinces along the border with Cambodia, Laos and Myanmar (Burma), 
also provinces: Kalasin, Krabi (Plai Phraya district), Nakhon Si Thammarat, 
Narathiwat, Pattani, Phang Nga (including the city of Phang Nga), Rayong, 
Sakon Nakhon, Songkhla, Surat Thani and Yala, in particular wooded  
areas in these provinces. Sporadic cases in other parts of Krabi province, 
in large cities and seaside resorts: Bangkok, Chiang Mai, Chiang Rai,  
Koh Samui, Koh Phangan, Phuket. No risk of transmission on the islands 
in Krabi province (Koh Phi Phi, Koh Yao Noi, Koh Yao Yai, Ko Lanta)  






or doxycycline — provinces 
along the border with Cambo-
dia, Laos and Myanmar (Bur-
ma), also provinces: Kalasin, 
Krabi (Plai Phraya district), 
Nakhon Si Thammarat,  
Narathiwat, Pattani, Phang  
Nga (including the city of 
Phang Nga), Rayong, Sakon 
Nakhon, Songkhla, Surat  
Thani and Yala; Bangkok, 
Chiang Mai, Chiang Rai, Koh 






Sporadic cases among the local population No data Repellents
Maldives Not found Not applicable Not applicable
Mauritius Not found Not applicable Not applicable
Seychelles Not found Not applicable Not applicable
Pacific Ocean
Fiji Not found Not applicable Not applicable
Palau Not found Not applicable Not applicable
Central America and the Caribbean
Belize Sporadic cases among the local population. No risk of transmission  




Not found Not applicable Not applicable
Costa Rica Not found Not applicable Not applicable
Æ
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Mexico Campeche, Chiapas, Chihuahua, Nayarit and Sinaloa districts; sporadic 
cases in Durango, Jalisco, Oaxaca, Sonora and Tabasco districts, and  
in Othon P. Blanco in the southern part of the Quintana Roo district  
along the border with Belize. No risk of transmission along the  
Mexican-American border
No atovaquone/proguanil, 
doxycycline, mefloquine or 
chloroquine — Campeche, 
Chiapas, Chihuahua, Nayarit 
and Sinaloa districts;
Durango, Jalisco, Oaxaca, 
Sonora, Tabasco districts and 
Othon P. Blanco In southern 
parts of Quintana Roo district 
— repellents
Red Sea
Egypt Not found Not applicable Not applicable
Mediterranean Sea
Croatia Not found Not applicable Not applicable
France Not found Not applicable Not applicable
Greece In 2016 malaria cases were found among the local population.  
12 districts were affected: Farkadona, Trikala, Palamas, Tempe,  
Achaean, Thebes (Central Greece), Evrotas, Andravida-Kyllini  
(Peloponnisos), Chalcis (Eubea), Marathon (Attica), Lagada, Pylaia  
(Thessaloniki)
No data atovaquone/proguanil, 
doxycycline or mefloquine in 
following districts: Farkadona, 
Trikala, Palamas, Tempe, 
Achaean, Thebes, Evrotas, 
Andravida-Kyllini, Chalcis,  
Marathon, Lagada, Pylaia
Spain Not found Not applicable Not applicable
Malta Not found Not applicable Not applicable
Tunisia Not found Not applicable Not applicable
Italy Not found Not applicable Not applicable
Table 5 cont. Recommended antimalarial chemoprophylaxis in countries popular among divers. Source: [37]
 — an extra pair of glasses or contact lenses (travellers 
with a sight defect);
 — sunglasses;
 — sunscreen, sunburn medication.
The contents of a travel health kit should be tailored 
to a traveller’s individual needs and health requirements, 
the length of stay and health risks prevalent in a  given 
destination area. All medicines are to be bought in Poland 
or other developed countries because reports show that 
medications manufactured in the developing world, e.g. 
in South-East Asia, have little therapeutic value. When 
travelling to Asia or Africa, Polish globetrotters often buy 
local drugs for diarrheal diseases, febrile conditions or 
malaria chemoprophylaxis. Their prices are much lower 
but so is their quality and therapeutic value. Before taking 
any medication, you should always read the patient infor-
mation leaflet containing the information on contraindica-
tions for use and possible drug interactions; travellers are 
recommended to note down the international names of 
the drugs they take regularly in case they lose their travel 
health kit or run out of the medications and we will have 
to buy substitutes [17].
INsurANcE
All recreational and professional divers travelling abroad 
are recommended to obtain a  travel insurance including 
coverage for medical treatment and assistance. Insurance 
companies offer a variety of insurance plans ranging from 
basic to full coverage. You need to remember that basic 
plans offer little coverage and contain a number of exclu-
sions, such as treatment of tropical diseases or treatment 
of injuries sustained from extreme sports. Travellers are 
also recommended to obtain an insurance including the 
coverage for medical evacuation and repatriation. If they 
are planning to engage in extreme sports, including diving, 
they should buy an insurance including coverage for rescue 
operation, as it is not normally covered by the accident 
insurance. Travelers should not forget about the luggage 
insurance as well because the loss of baggage may be 
financially painful for a  traveller, especially if it is diving 
equipment. Divers travelling abroad should rather opt for 
an extended insurance coverage which covers the costs 
of specialist treatment (e.g. hyperbaric oxygen therapy), 
the costs of a rescue operation at sea and the liability in-
surance (personal injury or property damage). The cost of 
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a policy may vary depending on a number of factors, e.g. 
recreational vs. technical diving, the diving depth (max. 
30 m or deeper than 30 m with specialist diving equipment), 
the general health condition of a diver (chronic diseases). 
An insurance company may refuse to pay compensation if 
an incident occurred as a result of intoxication by alcohol 
or drugs [17].
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